Home Search Abstracts Browse Sessions Program Committee View Session E-mail Abstract Author

 

 




Session 151 Poster Abstracts
Erectile Dysfunction and Hypogonadism
Friday, 1:30 - 3:30 pm
Hall B


876    
Changes in Androgens and Gonadotropins during HAART and Their Association with Development of Lipoatrophy in HIV-infected Men
D Wunder1, N Bersinger1, R Weber2, B Hirschel3, M Cavassini4, E Luigia5, P Schmid6, E Bernasconi7, O Keiser8, J Evison1, Hansjakob Furrer*1, and Swiss HIV Cohort Study
1Berne Univ Hosp, Switzerland; 2Zurich Univ Hosp, Switzerland; 3Geneva Univ Hosp, Switzerland; 4Univ Hosp, Lausanne, Switzerland; 5Basel Univ Hosp, Switzerland; 6St Gallen Hosp, Switzerland; 7Ospedale civico, Lugano, Switzerland; and 8Swiss HIV Cohort Study Data Ctr, Lausanne

Background:  Disorders of the androgens are prevalent in HIV-infected men. There is a controversy about an association of changes of androgens and development of lipoatrophy.

Methods:  We conducted a nested case control study of 99 ART-naïve HIV-infected men who started and continued a virologically successful zidovudine (AZT)/lamivudine (3TC)-based HAART for 2 years, during which 11 patients developed lipoatrophy. Of 128 patients in the Swiss HIV Cohort Study, we randomly chose 88 controls. Serum levels of luteinizing hormone (LH), follicle-stimulating hormone (FSH), free testosterone (FT), and dehydroepiandrosterone (DHEA) were measured in plasma stored before the start of and 2 years later of unchanged HAART.

Results:  Controls and cases did not differ with regard to age, body mass index, plasma HIV RNA, or CDC stage. CD4 counts at HAART start were higher in cases (median 440, IQR 173 to 556) than in controls (median 203, IQR 98 to 331), p = 0.04. At HAART start age adjusted FT levels were low in 69 (70%); in those LH levels were normal 48% and low in 43%. FSH levels were normal 83 (84%) and low in 12 (12%). These proportions did not differ significantly in cases and controls. DHEA levels were high in 26 (30%) and normal in 58 (66%) of controls and high in 1 (9%) and normal in 8 (73%) of the cases (p = 0.1). During 2 years of HAART significant changes of FT and FSH levels were not observed. However, controls increased their DHEA levels by a median of 1.3 IU/L (IQR –0.6 to 5.0) (p for change during HAART < 0.001) and differed in that from cases (p for change = 0.6). All cases showed an increase in LH levels (median difference +2.9 IU/L, IQR 0.8 to 5.5, p for change 0.003), while these consistent differences were not seen in control (median change –0.1, IQR –0.9 to 1.06). The presence of protease inhibitors in the regimen was not associated with any change. In a stepwise logistic regression model including baseline hormone values, changes of hormone values, age, body mass index, CD4 count, and HIV RNA development of lipoatrophy was associated with an increase in LH levels during HAART (p = 0.001) and there was a trend of association with a decrease in DHEA levels, lower body mass index, higher CD4 counts, higher HIV RNA, and increasing age (p = 0.05 to 0.1).

Conclusions:  Hypogonadism is found in the majority in HIV-infected men and does not resolve during 2 years of HAART. Development of lipoatrophy is associated with particular changes in the gonadotropin-androgen axis and characterised by an increase of LH levels and lack of increase of DHEA levels during HAART.

Keywords: androgens; gonadotropins; lipoatrophy